<DOC>
	<DOCNO>NCT02859896</DOCNO>
	<brief_summary>Primary Objective : Evaluate effect Hectorol® capsule reduce elevate level intact parathyroid hormone ( iPTH ) . Secondary Objectives : - Evaluate safety profile Hectorol® capsule versus Rocaltrol® ( calcitriol ) capsule . - Determine pharmacokinetic profile 1,25-dihydroxyvitamin D2 administration Hectorol® .</brief_summary>
	<brief_title>Safety Efficacy Hectorol Pediatric Patients With Chronic Kidney Disease Stage 3 4 With Secondary Hyperparathyroidism Not Yet Dialysis</brief_title>
	<detailed_description>The total study duration per patient approximately 28 week .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>1 alpha-hydroxyergocalciferol</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Inclusion criterion : Male female age 5 18 year old . Weight ≥15 kg . Chronic kidney disease ( CKD ) Stage 3 4 dialysis , define glomerular filtration rate ( GFR ) 15 59 mL/min/1.73m^2 ( establish Schwartz equation ) Week 2 visit . Intact parathyroid hormone ( iPTH ) value &gt; 100 pg/mL CKD Stage 3 &gt; 160 pg/mL CKD Stage 4 , Week 2 visit . Signed informed consent/assent form . Exclusion criterion : The patient serum 25hydroxyvitamin D level &lt; 30 ng/mL screening . The patient correct calcium ≥10 mg/dL Week 2 visit . The patient serum phosphorus &gt; 4.5 mg/dL child 13 18 year age ; &gt; 5.8 mg/dL child 5 12 year age Week 2 visit . The patient anticipate require maintenance hemodialysis within 3 month . The patient use cinacalcet vitamin D sterol therapy calcitriol , doxercalciferol , paricalcitol within 14 day prior baseline visit . The patient history , active , symptomatic heart disease within 12 month prior baseline ( Week 0 ) visit . The patient currently chronic gastrointestinal disease ( ie , malabsorption , severe chronic diarrhea , chronic ulcerative colitis , ileostomy ) . The patient currently primary hyperparathyroidism total parathyroidectomy . The patient active malignancy . The patient unable swallow capsule size similar Hectorol® Rocaltrol® capsule . The patient history sensitivity allergy doxercalciferol , calcitriol vitamin D analog . The patient currently use aluminum magnesiumbased binder . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>